Teleflex (TFX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Teleflex reported revenue of $764.38 million for the quarter ended September 2024, reflecting a year-over-year increase of 2.4% [1] - The earnings per share (EPS) for the quarter was $3.49, down from $3.64 in the same quarter last year, with an EPS surprise of +3.25% compared to the consensus estimate of $3.38 [1] Revenue Performance - Geographic Revenues in the Americas reached $433.30 million, slightly above the estimated $432.78 million, marking a +1.2% change year-over-year [3] - EMEA revenues were reported at $150.20 million, slightly below the estimate of $150.67 million [3] - Asia revenues totaled $98.30 million, exceeding the estimate of $96.66 million [3] Segment Performance - Net Revenues from Interventional products were $149.90 million, surpassing the average estimate of $144.74 million, with a year-over-year increase of +11.8% [3] - Interventional Urology revenues were $83.40 million, exceeding the estimate of $82.01 million, reflecting a +13.3% change year-over-year [3] - OEM revenues were reported at $82.60 million, below the estimate of $89.36 million, with a +0.4% change year-over-year [3] - Vascular Access revenues reached $180.90 million, above the estimate of $179.24 million, with a +6.5% year-over-year change [3] - Anesthesia revenues were $101.10 million, slightly below the estimate of $101.17 million, showing a +3.6% change year-over-year [3] - Other revenues were $54.80 million, below the estimate of $55.62 million, with a significant year-over-year decline of -28% [3] - Surgical revenues were reported at $111.70 million, below the estimate of $115.47 million, reflecting a -1% change year-over-year [3] Stock Performance - Teleflex shares have returned -3.6% over the past month, contrasting with the Zacks S&P 500 composite's +1% change [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [4]